交付 Hong Kong
获得最佳体验 获取应用程序
GZD824 Dimesylate is a novel orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I) with IC50 of 0.34 nM and 0.68 nM, respectively.
TrustPilot
苏雷什· K.
4天前
伊姆兰 F.
2 周前
Sneha T.
1 个月前